UpSwinG
Research type
Research Study
Full title
UpSwinG: Real World Study on TKI Activity in Uncommon mutations and Sequencing Giotrif
IRAS ID
274721
Contact name
Sanjay Popat
Contact email
Sponsor organisation
Boehringer Ingelheim International GmbH
Duration of Study in the UK
0 years, 10 months, 14 days
Research summary
This is a non-interventional, multi-country, multi-center cohort study being conducted in up to 11 countries. The study is fully retrospective, based on real world data and all patient data will be pseudonymised. The patients selected for the study will have a diagnosis of Non Small Cell Lung Cancer (NSCLC) with a particular type of mutation known as an EGFR mutation. They will also have been treated with a specific drug aimed at this disease (known as EGFR-TKIs) in accordance with regular clinical practice. Patients will be selected by the participating physicians based on the inclusion and exclusion criteria. Data will be extracted from medical records by members of the direct care team; it will be de-identified by assigning unique patient ID codes before being entered into the electronic case report form. No one outside of the direct care team will have access to identifiable patient data.
REC name
Wales REC 6
REC reference
19/WA/0345
Date of REC Opinion
29 Nov 2019
REC opinion
Favourable Opinion